2024
Albert Lehr
Psychedelics are a class of drugs that can occasion similar changes in conscious ex- periences mediated via the G-protein coupled Serotonin 2A receptor. These changes vary from slight distortions in perceptions to pseudohallucinations and the experienced cessation of a personal self distinct from and necessary for conscious experience, known as ego-dissolution. Psychedelics produce positive...
Neuroscience Applied
2024
Isabelle Straumann, Friederike Holze, Laura Ley et al.
24 citations
Psilocybin is being studied for its therapeutic potential in various mental health disorders, such as depression, anxiety, and addiction. Initial studies suggested that psilocybin is generally safe when used under controlled conditions, but more research is needed to better understand its safety profile. We report safety pharmacology data from a pooled analysis of three randomized crossover...
Research Square
December 28, 2023
Joshua M. Poulin, Gregory E. Bigford, Krista L. Lanctôt et al.
1 citation
preprint
Abstract Background: Major Depressive Disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phase trials suggest psilocybin...
December 26, 2023
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al.
preprint
Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-HT2A receptor. This comprehensive review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin.Areas of Uncertainty: Despite initial concerns that psilocybin could cause...
December 26, 2023
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al.
preprint
Background: Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsychiatric conditions, including conditions that have not benefited from prior interventions. The latter half of the twentieth century marked a revolution in the treatment of depression, anxiety, and psychosis, exemplified by the...
Theoretical and Natural Science
December 20, 2023
Jingxuan Chen
Psilocybin is a naturally occurring psychoactive compound, which has been used for ages in traditional settings for religious and therapeutic use. Recent studies have renewed interest in psilocybin for its potential therapeutic benefits in treating depression and anxiety. The pharmacodynamics of psilocybin are complex, involving its rapid conversion to psilocin and its activity on various...
Clinical Psychopharmacology and Neuroscience
November 30, 2023
Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim et al.
16 citations
Previous studies suggested effectiveness of psilocybin in the field of mental health. FDA designated psilocybin as a "breakthrough therapy" for the treatment of treatment-resistant depression (TRD) in 2018. This paper provided a review of psilocybin's potential role in treatment of depression by focusing on published clinical trials. Studies showed that psilocybin, an agonist on 5-HT2A...
JMIR Formative Research
November 28, 2023
George Danias, Jacob Appel
13 citations
Background Psychedelic substances have demonstrated promise in the treatment of depression, anxiety, and substance use disorders. Significant media coverage has been dedicated to psychedelic medicine, but it is unclear whether the public associates psilocybin with its potential therapeutic benefits. The COVID-19 pandemic led to an increase in depression, anxiety, and substance abuse in the...
Journal of Medicinal Chemistry
November 20, 2023
Kaveh Matinkhoo, Lisa Yu, David Press et al.
18 citations
The psychedelic prodrug psilocybin has shown therapeutic benefits for the treatment of numerous psychiatric conditions. Despite positive clinical end points targeting depression and anxiety, concerns regarding the duration of the psychedelic experience produced by psilocybin, associated with enduring systemic exposure to the active metabolite psilocin, pose a barrier to its therapeutic...
Journal of Sociology, Psychology & Religious Studies
November 6, 2023
Sarah Naher, Sarah Naher
1 citation
Mental illnesses pose social, economic, and health burdens worldwide. The increasing health burden and mental diseases pose the need for investigating other potential medications. The present review focuses on psychedelic medications. The Patient/Participant, Intervention, Outcomes, and Studies ([PICOS) protocol and the Preferred Reporting Items for Systematic Reviews (PRISMA) checklist guided...